Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 8/20 | 0.55 |
| ▸ | HRH1 | P35367 | 6/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.55 |
| ▸ | HTR1D | P28221 | 3/20 | 0.55 |
| ▸ | HTR1B | P28222 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | HTR7 | P34969 | 3/20 | 0.55 |
| ▸ | HTR2B | P41595 | 3/20 | 0.55 |
| ▸ | HTR1A | P08908 | 3/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.55 |
| ▸ | HRH2 | P25021 | 2/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12868566 | 0.78 | CYP1A2 (0.97) | CYP1A2CYP2D6HTR6HRH1ADRA2A | |
| SCHEMBL3863830 | 0.76 | HDAC6 (0.50) | CYP1A2SIGMAR1ALDH1A1TSHRHDAC1 | |
| SCHEMBL22055416 | 0.75 | HDAC6 (0.49) | CYP1A2CYP2D6HTR6HRH1ADRA2A | |
| SCHEMBL1840161 | 0.75 | HTR2C (0.50) | CYP1A2CYP2D6HTR2AHTR2CKDM4E | |
| SCHEMBL3861822 | 0.73 | CYP1A2 (0.51) | CYP1A2CYP2D6HTR6HRH1ADRA2A | |
| SCHEMBL3857088 | 0.73 | CYP1A2 (0.51) | CYP1A2CYP2D6HTR6HRH1ADRA2A | |
| SCHEMBL3857059 | 0.72 | CYP1A2 (0.49) | CYP1A2CYP2D6HTR6HRH1ADRA2A | |
| SCHEMBL22054358 | 0.72 | ADRA2A (0.61) | CYP1A2CYP2D6HTR6HRH1ADRA2A | |
| SCHEMBL16024480 | 0.71 | DRD3 (1.00) | CYP1A2CYP2D6HTR6HRH1ADRA2A | |
| SCHEMBL12457645 | 0.71 | HTR2A (0.71) | CYP1A2CYP2D6HTR6HRH1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581221-B1 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7592454-B2 | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1581221-A4 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2008-11-26 | — | — | EP | disclosed |
| US-7109339-B2 | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050239768-A1 | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-27 | — | — | US | disclosed |
| EP-1581221-A2 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040180875-A1 | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| WO-2004056324-A2 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180875-A1 | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists | HTR1A, HTR7, HTR5A | CYP1A2 764/4885CYP2D6 948/4885HTR6 36/4885 |
| US-20050239768-A1 | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists | HTR1A, HTR7, HTR1D | CYP1A2 432/4885CYP2D6 219/4885HTR6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.